(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 41.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Alnylam Pharmaceuticals's revenue in 2025 is $2,461,963,000.On average, 12 Wall Street analysts forecast ALNY's revenue for 2025 to be $464,280,822,498, with the lowest ALNY revenue forecast at $438,552,371,276, and the highest ALNY revenue forecast at $500,590,758,285. On average, 12 Wall Street analysts forecast ALNY's revenue for 2026 to be $692,024,319,268, with the lowest ALNY revenue forecast at $557,753,005,936, and the highest ALNY revenue forecast at $997,458,872,544.
In 2027, ALNY is forecast to generate $919,338,007,947 in revenue, with the lowest revenue forecast at $706,395,298,156 and the highest revenue forecast at $1,388,782,163,925.